129 related articles for article (PubMed ID: 8383519)
21. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Moog R; Burger AM; Brandl M; Schüler J; Schubert R; Unger C; Fiebig HH; Massing U
Cancer Chemother Pharmacol; 2002 May; 49(5):356-66. PubMed ID: 11976829
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.
Postmus PE; Schramel FM; Smit EF
Semin Oncol; 1998 Aug; 25(4 Suppl 9):79-82. PubMed ID: 9728590
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
[TBL] [Abstract][Full Text] [Related]
24. Determination of the antimetabolite Gemcitabine (2',2'-difluoro-2'-deoxycytidine) and of 2',2'-difluoro-2'-deoxyuridine by 19F nuclear magnetic resonance spectroscopy.
Edzes HT; Peters GJ; Noordhuis P; Vermorken JB
Anal Biochem; 1993 Oct; 214(1):25-30. PubMed ID: 8250231
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
[TBL] [Abstract][Full Text] [Related]
27. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
Hansen LT; Lundin C; Helleday T; Poulsen HS; Sørensen CS; Petersen LN; Spang-Thomsen M
Lung Cancer; 2003 May; 40(2):157-64. PubMed ID: 12711116
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes.
Rygaard K; Slebos RJ; Spang-Thomsen M
Int J Cancer; 1991 Sep; 49(2):279-84. PubMed ID: 1652570
[TBL] [Abstract][Full Text] [Related]
29. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.
Limmer S; Hahn J; Schmidt R; Wachholz K; Zengerle A; Lechner K; Eibl H; Issels RD; Hossann M; Lindner LH
Pharm Res; 2014 Sep; 31(9):2276-86. PubMed ID: 24599802
[TBL] [Abstract][Full Text] [Related]
31. Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Li M; Li H; Cheng X; Wang X; Li L; Zhou T; Lu W
Pharm Res; 2013 May; 30(5):1400-8. PubMed ID: 23344908
[TBL] [Abstract][Full Text] [Related]
32. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro.
Pedersen MW; Holm S; Lund EL; Højgaard L; Kristjansen PE
Neoplasia; 2001; 3(1):80-7. PubMed ID: 11326319
[TBL] [Abstract][Full Text] [Related]
33. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
[TBL] [Abstract][Full Text] [Related]
37. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
38. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
Masters GA; Declerck L; Blanke C; Sandler A; DeVore R; Miller K; Johnson D;
J Clin Oncol; 2003 Apr; 21(8):1550-5. PubMed ID: 12697880
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Guechev A; Smid K; Loves WJ; Vermorken JB; Postmus PE; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):407-15. PubMed ID: 9933029
[TBL] [Abstract][Full Text] [Related]
40. [Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7].
Tong Q; Shu XG; Lu XM; Li WY; Tao KX; Chen DD; Wang GB
Yao Xue Xue Bao; 2009 Feb; 44(2):181-7. PubMed ID: 19408690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
